The company had posted a consolidated net profit of Rs 384.35 crore in the same period last fiscal, Aurobindo Pharma said in a BSE filing.
Net sales during the period under review stood at Rs 3,432.08 crore. In the corresponding period previous fiscal, the sales were Rs 3,142.46 crore, it added.
During the previous year on December 4, 2014 the company's US arm Aurobindo Pharma USA Inc had acquired Natrol LLC. The above consolidated results include that of Natrol and therefore the corresponding figures are not comparable, Aurobindo said.
Shares of Aurobindo Pharma ended the day at Rs 743.30 apiece, down 0.43 per cent from the previous close on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%